日本語 
Kura Oncology, Inc., and Kyowa Kirin Co., Ltd. announced Kura submitted a New Drug Application (NDA) for ziftomenib, a highly selective, once-daily, oral, investigational menin inhibitor, for the treatment of…
Latest News
Takaoka Hospital Adopts BizRobo! for Medical DX Reform
Open Co., Ltd., a subsidiary of the Open Group Co., Ltd., is…
Alpha Fusion, Curadh MTR Partner on Astatine-211 Drugs
Alpha Fusion, Inc. and Curadh MTR, Inc. They plan to create a…
PHC secures exclusive rights to MaxCyte ExPERT in Japan
The Biomedical Division of PHC Corporation, a subsidiary of PHC Holdings Corporation…
DRC Medicine Ltd to Merge with Ribbon Acquisition Corp.
DRC Medicine Ltd., an innovative healthcare and biotechnology company based in Tokyo,…
PRD Therapeutics Begins First Human Trial for PRD001
PRD Therapeutics Inc. has announced a first-in-human clinical trial for PRD001. This is…
AGC Biologics Grows Cell Therapy Presence in Asia
AGC Biologics, your friendly CDMO expert, will commence cell therapy process development…
Axcelead, A2 Healthcare Unite for Pharma R\&D in Japan
Axcelead, Inc., A2 Healthcare Corporation and another company have formed a partnership.…
Fujirebio Acquires PSG to Boost Biological Material Supply
H.U. Group Holdings Inc., through its wholly owned subsidiary Fujirebio Holdings, Inc.…
Latest Article
English